Biomarin prepares for European approval of Ascendis competitor
US firm Biomarin has upgraded its financial expectations based on Q2, and is preparing a new drug that will challenge the existing market.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT AND CHRISTOFFER ØSTERGAARD
US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA extends review period for Ascendis Pharma's first drug
For subscribers
